Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Biora is a drug-device company developing smart pills for GI diseases and enabling oral delivery of biologics.</li><li>Its pipeline features two assets: NaviCap, for targeted drug delivery in GI diseases & BioJet, for oral delivery of biologics.</li><li>NaviCap's BT-600 trial has completed the SAD & MAD cohorts & should report results in June.</li></ul>

Biora is a drug-device company developing smart pills for GI diseases and enabling oral delivery of biologics.Its pipeline features two assets: NaviCap, for targeted drug delivery in GI diseases & BioJet, for oral delivery of biologics.NaviCap's BT-600 trial has completed the SAD & MAD cohorts & should report results in June.

<ul><li>Biora is a drug-device company developing smart pills for GI diseases and enabling oral delivery of biologics.</li><li>Its pipeline features two assets: NaviCap, for targeted drug delivery in GI diseases & BioJet, for oral delivery of biologics.</li><li>NaviCap's BT-600 trial has reported its SAD & MAD topline & will advance to a Phase Ib. BioJet is on the cusp of a deal & may advance into the clinic through the efforts of pharma partners.</li></ul>

Biora is a drug-device company developing smart pills for GI diseases and enabling oral delivery of biologics.Its pipeline features two assets: NaviCap, for targeted drug delivery in GI diseases & BioJet, for oral delivery of biologics.NaviCap's BT-600 trial has reported its SAD & MAD topline & will advance to a Phase Ib. BioJet is on the cusp of a deal & may advance into the clinic through the efforts of pharma partners.

<ul><li>Biora is a drug-device company developing smart pills for GI diseases and enabling oral delivery of biologics.</li><li>Its pipeline features two assets: NaviCap, for targeted drug delivery in GI diseases & BioJet, for oral delivery of biologics.</li><li>NaviCap is poised for IND clearance and BioJet may advance into the clinic through the efforts of pharmaceutical partners.</li></ul>

Biora is a drug-device company developing smart pills for GI diseases and enabling oral delivery of biologics.Its pipeline features two assets: NaviCap, for targeted drug delivery in GI diseases & BioJet, for oral delivery of biologics.NaviCap is poised for IND clearance and BioJet may advance into the clinic through the efforts of pharmaceutical partners.

United States

Biora Therapeutics, Inc. provides health care testing services. The Company offers complex molecular diagnostic solutions. Biora Therapeutics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biora Therapeutics (BIOR US)

BIOR: Second Quarter Results

Biora is a drug-device company developing smart pills for GI diseases and enabling oral delivery of biologics. Its pipeline features two assets:...

Zacks Small Cap Research

BIOR: BT-600 Topline

Biora is a drug-device company developing smart pills for GI diseases and enabling oral delivery of biologics. Its pipeline features two assets:...

Zacks Small Cap Research

BIOR: BT-600 Data in June

Biora is a drug-device company developing smart pills for GI diseases and enabling oral delivery of biologics. Its pipeline features two assets:...

Zacks Small Cap Research

BIOR: BT-600 Data in June

Biora is a drug-device company developing smart pills for GI diseases and enabling oral delivery of biologics. Its pipeline features two assets:...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)